Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Paladin acquires Dimethaid unit with Pennsaid licence Add to ...

Paladin Labs Ltd. has acquired Dimethaid Health Care Ltd., which owns the Canadian licence for Pennsaid, a lotion to treat osteoarthritis in the knee. Montreal-based Paladin said it paid the parent company, Dimethaid Research Inc., an undisclosed upfront payment. Markham, Ont.-based Dimethaid will also receive a share in operating profit above minimum targets and a long-term supply accord for the lotion, which is expected to generate sales of $8-million to $9-million by the end of 2005, Paladin said. DMX (TSX) rose 0.5 cents to 26 cents. PLB (TSX) fell 15 cents to $5.20.

Report on Business Company Snapshots are available for:

Follow us on Twitter: @GlobeBusiness

 

In the know

Most popular video »

Highlights

More from The Globe and Mail

Most Popular Stories